| Autor: |
Li Zhang, Ping Li, Xiangmei Chen, Xuefeng Sun, Yiqing Wu, Hong-li Lin, Guangyan Cai, Shuting Pan, Dinghua Chen |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
BMJ Open, Vol 13, Iss 2 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2044-6055 |
| DOI: |
10.1136/bmjopen-2022-068864 |
| Popis: |
Introduction Roxadustat is a first-in-class oral therapy that treats chronic kidney disease (CKD) anaemia with the benefit of a novel mechanism of action that consistently corrects and maintains haemoglobin (Hb) across the spectrum of non-dialysis-dependent (NDD) CKD anaemia with an acceptable safety profile.Methods and analysis This is a randomised, control, open-label, multicentre trial. About 250 adult Chinese participants with stage 3–5 CKD NDD in approximately 30 centres will be enrolled, randomly assigned in a 1:1 ratio, to receive a 16-week treatment and 4-week follow-up. The interventions for study arm are |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
